The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
The Efficacy Of An Intervention For PTSD Among Illicit Drug Users
Funder
National Health and Medical Research Council
Funding Amount
$580,219.00
Summary
The high prevalence of PTSD among people with illicit drug use disorders (IDUD) has been clearly recognised in both the Australian and international literature. In Australia, 33% of those with opioid use disorders and 24% of those with amphetamine use disorders have comorbid PTSD. The prevalence among people with alcohol use disorders on the other hand, is comparably low (5%). Despite the high prevalence of PTSD among people with IDUD, research on treatment responses to this significant problem ....The high prevalence of PTSD among people with illicit drug use disorders (IDUD) has been clearly recognised in both the Australian and international literature. In Australia, 33% of those with opioid use disorders and 24% of those with amphetamine use disorders have comorbid PTSD. The prevalence among people with alcohol use disorders on the other hand, is comparably low (5%). Despite the high prevalence of PTSD among people with IDUD, research on treatment responses to this significant problem is sparse. Individuals with this comorbidity present a significant challenge to substance abuse treatment providers as they present with a poorer clinical profile, and have poorer treatment outcomes, including higher readmission rates. Consequently, they are a costly burden to the health care system. The costs of this comorbidity to individual sufferers and society may be reduced substantially by the implementation of an integrated treatment that addresses both disorders concurrently. There is however, little research to guide how best to treat comorbid IDUD and PTSD. Although a small number of interventions have been developed and trialled, none have been evaluated in an Australian setting. One intervention which has shown promise in the United States is Concurrent Treatment of PTSD and Substance Use Disorder (CTPSD). Preliminary research has shown that CTPSD can be used safely and is effective in the treatment of PTSD among individuals with cocaine dependence. Completers of the program have demonstrated significant reductions in all PTSD symptom clusters and cocaine use from baseline to end of treatment which were maintained at 6 month follow-up. Significant reductions in depressive symptoms were also observed. Despite these promising results, CTPSD is yet to undergo a randomised controlled trial. The proposed study is a randomised controlled trial of the efficacy of CTPSD in the Australian setting.Read moreRead less
Cannabis and the brain: the good, the bad and the unknown. Cannabis is the most widely used illicit drug but much remains unknown about how it affects the brain. This research will examine effects on brain cells through to whole brain function in humans to determine how cannabis use may lead to impaired thinking or psychological symptoms and why cannabis might affect individuals in different ways.
Improving Treatment Responses For Co-occurring Mental And Substance Use Disorders
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
Mental and substance use disorders are two of Australia's most prevalent and burdensome health conditions, and they frequently co-occur. My program of research aims to improve our limited understanding of, and ability to successfully treat, mental and substance use disorders; with a view to improving the lives of the 3 million Australians who suffer from these disorders each year.
Defining The Clinical Role Of Topiramate In The Treatment Of Alcohol Dependence In Australia
Funder
National Health and Medical Research Council
Funding Amount
$718,836.00
Summary
We urgently require new strategies for the treatment of alcohol dependence. The effectiveness of currently approved alcohol medications is limited. Emerging data suggests that topiramate has robust effectiveness and that better medicine selection is possible for patients based on their genotype. We propose to conduct a double-blind randomised controlled trial to examine the clinical and cost effectiveness of topiramate using a genetically based personalised approach.
Randomised Double-blind Placebo-controlled Study Of Lisdexamfetamine For The Treatment Of Methamphetamine Dependence
Funder
National Health and Medical Research Council
Funding Amount
$1,303,735.00
Summary
Addiction to methamphetamines (‘ice’) is a growing community problem linked to serious disease and death. Current counselling approaches have limited success on their own, and more effective treatments linked to medications are needed. Lisdexamfetamine is a newly licenced stimulant medication with great promise in treating these patients. This trial will examine whether lisdexamfetamine (with counselling) safely reduces methamphetamine use and improves health and wellbeing among heavy users.
An RCT Of Cannabinoid Replacement Therapy (Sativex®) For The Management Of Treatment-resistant Cannabis Dependent Patients
Funder
National Health and Medical Research Council
Funding Amount
$788,133.00
Summary
This project is the first-ever outpatient RCT to test if the pharmaceutical cannabinoid Sativex can safely and cost-effectively deliver better treatment outcomes for patients seeking treatment for chronic cannabis dependence. Sativex is a mouth spray with equal parts THC and cannabidiol, and appears to have a safer pharmacological profile than illicit cannabis or synthetic THC alone. Thus Sativex may lead to lower rates of psychiatric adverse events and increased cannabis abstinence rates.